anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Each year, 500,000 patients in the US suffer a cardiac arrest and a growing number of them are resuscitated using ECPR. However, neurologic and renal injury remain important resulting comorbidities. The pathophysiology of these often-devastating injuries is ischemia (inadequacy of blood flow, at times compounded by hypoxemia) followed by an abrupt reperfusion (ECMO flow initiation). Among patients with congenital heart disease (CHD) receiving ECPR, 52% either die prior to discharge or suffer severe neurologic impairment. Diatomic hydrogen (H2) administration during and following ECPR may chemically reduce the toxic mediators that directly damage cellular structures and improve neurologically intact survival.

Preclinical data. Several groups have described that H2 inhalation decreases injury when administered following ischemic stroke, myocardial infarction, and cardiac arrest in rodents. Our group demonstrated that inhalation of 2.4% H2 for 24 hours following an experimental swine ischemia-reperfusion injury (as occurs in ECPR) improved neurologic scores, decreased seizures, diminished T2 white matter injury volume by 65%, and improved serum creatinine. Safety study in healthy participants. Under an investigator-initiated IND, we exposed 8 healthy adult participants to up to 72 hours of 2.4% H2 inhalation via high flow nasal cannula, finding no adverse effects on markers of hepatic, renal, cardiac or pulmonary function and no clinically significant symptoms reported. Having received a favorable pre-IND review from the FDA, we propose a two-center early phase study of H2 administration in patients with CHD receiving ECPR.

Study overview. We propose an early-phase randomized trial entitled the 'Hydrogen FAST Trial' (Hydrogen's Feasibility And Safety as a Therapeutic agent). The trial will have a 3-patient vanguard phase and 53 patients with CHD experiencing ECPR randomly assigned in a 3:2 (32/21) ratio to either usual care plus 2% H2 gas for 72 hours or to usual care. Patients will be recruited from two sites. We will primarily examine feasibility and safety (severe adverse events, independently adjudicated), as well as some indicators of efficacy.

Hypotheses. Feasibility endpoint: We hypothesize that H2 gas will be administered for \>90% of the first 72 post-arrest hours in patients so-assigned and will be environmentally safe. Safety endpoint: We hypothesize that compared with patients receiving usual post-arrest care, patients receiving H2 will not exceed the treatment-related SAE rate of the usual care group by \>12.5% in the 30 days following randomization.
Approximately 2% to 4% of college-aged women suffer from eating disorders (EDs), and many more are at risk of developing them. A previous Internet-based intervention called Student Bodies (SB), which focused on body image concerns, was effective in reducing risk factors for EDs among college-aged women. However, the original SB program did not account for certain other risk factors, such as depression and compensatory behaviors like self-induced vomiting, over-exercising, or use of diuretics. Image and Mood (IaM) is an enhanced version of the SB program and takes into account depressive symptoms and the use of compensatory behaviors. This study will examine whether IaM will reduce ED risk factors in a large population of college women who are at high risk of developing EDs.

Participation in this study will last 10 weeks. Participants will be randomly assigned to either receive the IaM program or be placed on a wait list. The IaM program, which will be delivered through the Internet, will provide information about nutrition, exercise, body image, and coping skills-including examples and exercises. It will also include an online message board monitored by a study psychologist. Each week the IaM participants will monitor their behavior, keep a journal about their experiences, and answer self-report questionnaires. Assessments of eating disorder symptoms; weight and shape concerns; depressive symptoms; and incidence of substance abuse, anxiety, or depressive disorders will be completed post-treatment and at 1- and 1.5-month follow-ups. Those assigned to the wait list will complete these assessments and then receive the IaM program after the last follow-up.
The invention describes the realisation of transmission link optimisation in a situation, where a mobile station has moved from a network area controlled by a first radio network controller (RNC) RNC1 to a network area controlled by a second radio network controller RNC2. Signalling associated with the procedure is executed between the two RNC:s and a mobile switching center (MSC). The mobile station does not need to participate in the signalling, since the used radio resources remain the same. The object of this procedure is to optimise the utilisation of transmission links in the radio access network being used (RAN) and to minimise the transmission delay between the controlling RNC and the radio interface. This is realised by relocating the entities which control connections of a mobile station from the first RNC to the second RNC, and optimising the transmission links between the MSC and the second RNC. Such controlling entities may comprise e.g. the macrodiversity combining function, radio resource control block and associated user plane entities.
A cosmetic composition is disclosed comprising at least one Polyhydroxyalkanoate (PHA) in the form of particles having an average diameter (d 50) of 0.1nm to 50 pm. The PHA can comprise 0.1% w/w to 30% w/w of the total cosmetic composition, and some embodiments can use 1%w/w to 8%w/w. The composition may comprise a silicone external phase or may be in the form of a loose or compacted powder. Various PHAs can be used, although advantageously, the PHAs can have a chain length of 1 to 8 carbons. In some embodiments, the PHA can be selected to have an oil absorption of 60 to 150 grams of a desired oil per 100 grams of PHA, where the desired oil can be, for example, sebum. Further, the composition may optionally include one or more pigments. In use, the composition may be applied to the skin or hair of a user.
Use of naringin dihydrochalcone in preparing a medicament for eliminating phlegm and/or treating chronic obstructive pulmonary disease. Phlegm is formed due to changes in the composition of respiratory fluids when inflammation occurs in the respiratory tract. Our experimental research indicates that ND can increase the secretion of phenol red from the airways, having a good expectorant effect. Chronic obstructive pulmonary disease is a chronic disease of the respiratory system, with the excessive production of airway mucus proteins being an important pathological characteristic of COPD. Excessive secretion of mucus can lead to airway obstruction, restricted airways, impaired gas exchange, and bacterial colonization, thereby accelerating the decline in FEV1. Mucin 5AC (MUC5AC) determines the viscosity of mucus, and the expression of MUC5AC in COPD is significantly increased. ND can inhibit the expression of MUC5AC to help the EGF-induced excessive secretion of cell mucus, providing an experimental basis for the treatment of excessive mucus secretion in COPD with ND.
INTRODUCTION: Hysterectomy is one of the most common major gynecological surgeries, and it is performed for benign and malignant reasons. Currently, five types of hysterectomies are described: vaginal (VH), abdominal (AH), laparoscopic (LH), robotic, and vNOTES (vaginal natural orifice transluminal endoscopic surgery). This paper compares these two types of surgery in obese patients by analyzing the surgeries performed by our team.
MATERIALS AND METHODS: The research was conducted from January 2022 to December 2023 at the Department of Gynecology and Obstetrics of the General Hospital in Zadar. The study included female patients aged 18-75 years with a BMI > 30 kg/m2, regardless of parity, who were operated on for benign pathology.
RESULTS: There were 24 patients included in total. One conversion was observed in the TLH group because of excessive bleeding. Median operative time (IQR) was significantly lower in the vNOTES group (p < 0.05) than in the TLH group 35 (10.9) vs 125 (74.0) min.
CONCLUSION: The results concerning the duration of surgery, conversion rate, and postoperative bleeding and complications show that vNOTES hysterectomies seem to be feasible for obese patients. Further studies are needed to confirm these observations.
PULMICORT FLEXHALER is available as a dry powder for inhalation containing budesonide in the following 2 strengths: 90 mcg and 180 mcg. Each dosage strength contains 60 or 120 actuations per device.   


180 mcg/dose (NDC 54868-5844-0) with a target fill weight of 225 mg (range 200-250). 

PULMICORT FLEXHALER consists of a number of assembled plastic details, the main parts being the dosing mechanism, the storage unit for drug substance, and the mouthpiece. The inhaler is protected by a white outer tubular cover screwed onto the inhaler. The body of the inhaler is white and the turning grip is brown. The PULMICORT FLEXHALER inhaler cannot be refilled and should be discarded when empty. 

The number in the middle of the dose indicator window shows how many doses are left in the inhaler. The inhaler is empty when the number zero (“0”) on the red background reaches the middle of the window. If the unit is used beyond the point at which the zero reaches the middle of the window, the correct amount of medication may not be obtained and the unit should be discarded. 

Store in a dry place at controlled room temperature 20-25°C (68-77°F) [see USP] with the cover tightly in place. Keep out of the reach of children.
N6-methyladenosine (m6A) is the most prevalent internal modification in mammalian messenger RNAs and is associated with numerous biological processes. However, its role in chromosomal instability remains to be established. Here, we report that an RNA m6A methyltransferase, METTL16, plays an indispensable role in the progression of chromosome segregation and is required to preserve chromosome stability in colorectal cancer (CRC) cells. Depletion or inhibition of the methyltransferase activity of METTL16 results in abnormal kinetochore-microtubule attachment during mitosis, leading to delayed mitosis, lagging chromosomes, chromosome mis-segregation and chromosomal instability. Mechanistically, METTL16 exerts its oncogenic effects by enhancing the expression of suppressor of glucose by autophagy 1 (Soga1) in an m6A-dependent manner. CDK1 phosphorylates Soga1, thereby triggering its direct interaction with the polo box domain of PLK1. This interaction facilitates PLK1 activation and promotes mitotic progression. Therefore, targeting the METTL16-Soga1 pathway may provide a potential treatment strategy against CRC because of its essential role in maintaining chromosomal stability.
Cardiovascular diseases are an array of age-related disorders, and accumulating evidence suggests a link between cardiac resident macrophages (CRMs) and the age-related disorders. However, how does CRMs alter with aging remains elusive. In the present study, aged mice (20 months old) have been employed to check for their cardiac structural and functional alterations, and the changes in the proportion of CRM subsets as well, followed by sorting of CRMs, including C-C Motif Chemokine Receptor 2 (CCR2)+ and CCR2- CRMs, which were subjected to Smart-Seq. Integrated analysis of the Smart-Seq data with three publicly available single-cell RNA-seq datasets revealed that inflammatory genes were drastic upregulated for both CCR2+ and CCR2- CRMs with aging, but genes germane to wound healing were downregulated for CCR2- CRMs, suggesting the differential functions of these two subsets. More importantly, inflammatory genes involved in damage sensing, complement cascades, and phagocytosis were largely upregulated in CCR2- CRMs, implying the imbalance of inflammatory response upon aging. Our work provides a comprehensive framework and transcriptional resource for assessing the impact of aging on CRMs with a potential for further understanding cardiac aging.
PURPOSE: An alkyl glycoside having anti-aging or an alkyl glycoside mixture are provided to protect sensitive skin to a cosmetic product composition. CONSTITUTION: A formulation contains mixture of 1 or more alkyl glycoside or 2 or more alkyl glycoside in a cosmetic composition. The formulation prevents or delays signal of skin aging and lowers the effects. The alkyl glycoside or alkyl glycoside of mixture has chemical formula, (S)-O-R1. (S) is oligosaccharide comprising sequence of 2-8 same or different saccharide units. R1 is alkyl group containing 1-24 carbon atoms.
The invention belongs to the technical field of poultry vaccine, and particularly relates to an avian infectious bronchitis viral antigen for hemagglutination or hemagglutination inhibition tests on avian infectious bronchitis viruses and a preparation method thereof. The avian infectious bronchitis viral antigen comprises a virus solution and an assisting agent. The virus solution is applicable to respiratory type IBV-M41 strain, glandular stomach type IBV-YBX strain or kidney type IBV-T strain virus seeds. The assisting agent is any one stabilizer of gelatin, sucrose, polyethylene glycol, mannan oligosaccharide or chitosan. The specificity of an infectious bronchitis hemagglutination antigen is high, and the infectious bronchitis hemagglutination antigen is positive to the positive serum reaction of infectious bronchitis and is negative to the positive serum reaction of newcastle disease, bird flu and egg drop syndrome. By virtue of the respiratory type IBV-M41 strain, glandular stomach type IBV-YBX strain or kidney type IBV-T strain virus seeds and the stabilizer, after the avian infectious bronchitis viral antigen is stored for 5 years at the temperature of 2-8 DEG C, the valence is equal to or greater than 8Log2, and the stability is high.
Ketogenic diet therapy (KDT) is well established for the treatment of early epileptic encephalopathies and specific aetiologies; however, the impact on growth in infancy remains controversial. Our aim was to examine the influence of early KDT on growth velocity and height percentiles completing two tasks. First, we systematically reviewed the literature on growth in infants younger than 12 months. Second, we analysed data from our prospective database, including infants <12 months (n = 63) treated with KDT. The literature review (n = 7) remains descriptive and includes growth percentiles and z-scores as growth velocity was not described. Studies up to 2010 used fasting, calorie restrictions, and ratios >3:1. In individual cases, significant growth delays were found; other authors did not find any changes in growth parameters. Study endpoints in our own cohort included z-scores of growth velocity, standard deviation (SD) of height, weight, BMI, deviation from individual height percentile, and daily macronutrient intake. The median z-score of growth velocity was 1.03 (first year of life). After three months, median daily intake of protein and energy was 1.68 g/kg and 85 kcal/kg. Until the age of one year, neither growth velocity nor individual growth percentiles decreased. Infants showed distinct growth improvements at three months, likely due to continuous nutritional monitoring and reduction in seizures. In the second year of life, z-scores of growth velocity decreased in patients still receiving KDT (from 1.03 at 12 months to -1.5 at 24 months). Furthermore, younger age at epilepsy onset and at KDT start correlated with slower growth velocities in the first year of life. With appropriate nutritional intake and monitoring, KDT does not reduce growth in the first year of life. Future directions might be to study the impact of KDT on growth velocity and growth hormones throughout childhood.
After group A has finished the 8-week static stretching training, group B starts with the 8-week home-based proprioceptive neuromuscular facilitation stretching training. Altogether, 10 stretches are performed per leg 4 times a week.
Thrombotic antiphospholipid syndrome (TAPS) is characterized by thrombosis and persistently positive tests for antiphospholipid antibodies or lupus anticoagulant (LAC). Triple-positive APS has the highest risk of recurrent thrombosis, but no studies have focused on recurrent thrombosis in patients with single-positive TAPS. We conducted a retrospective cohort study of patients with single-positive TAPS diagnosed at Lifespan Health System, Rhode Island, to determine the rates and risk factors for recurrent thrombosis. Between January 2001 and April 2022, 128 patients were assessed who had single-positive APS (LAC = 98, aCL = 21, aβ2GPI = 9) and who had been followed for a total of 1453.8 patient-years (median follow-up 3.04 years). The initial antithrombotic regimen was warfarin in 44 %, a direct oral anticoagulant (DOAC) in 34 %, enoxaparin in 2 %, and no antithrombotic therapy or antiplatelet therapy only in 20 %. Recurrent thrombosis occurred in 16 (12.5 %) with a recurrent thrombosis rate of 3.08 per 100 patient-years. Systemic lupus erythematosus was the only variable significantly associated with recurrent thrombosis in a model adjusted for age, sex, body mass index, and type of positive APS test. All 16 patients with recurrent thrombosis were initially treated with warfarin, and, at the time of recurrent thrombosis, 13 patients remained on warfarin and three were off anticoagulation. In conclusion, the recurrent thrombosis rate in single-positive APS is low, and not all patients with a single-positive test may need indefinite anticoagulation with warfarin. Larger prospective studies are required to confirm this finding and establish optimal anticoagulation regimens for low-risk TAPS.
The present invention discloses a trifluoromethyl containing quinazoline derivative and a preparation method and application thereof. The preparation method comprises the following steps of: under the condition that copper and ligand exist, an N-cyano substituted aryl carboxamides compound reacting with a togni reagent in a solvent, and after completion of the reaction, obtaining the trifluoromethyl containing quinazoline derivative after treatment. The reaction substrate is readily available, the operation is convenient, the obtained quinazolinone derivative is of rich diversity, the required reaction condition is mild, and the reaction time is short. The all-in-one-pot reaction is realized, and not only a structural mother kernel of quinazoline is obtained, but also trifluoromethyl is introduced into the mother kernel structure. And the quinazolinone compound contains the spiropyran compound can be synthesized, which cannot be achieved by the prior art. The obtained product has good activity in inhibiting enzyme acetylcholinesterase and butyrylcholinesterase.
BACKGROUND: The utilization of postdilatation in primary percutaneous coronary intervention (PCI) is feared to induce suboptimal coronary blood flow and compromise the outcome of the patients. This meta-analysis sought to verify whether postdilatation during primary PCI is associated with worse angiographic or long-term clinical outcomes.
METHODS: Systematic literature searches were conducted on PubMed, The Cochrane Library, ClinicalTrials.gov, EBSCO, and Europe PMC on 10 March 2024. Eligible studies reporting the outcomes of postdilatation among ST-segment elevation myocardial infarction patients were included. The primary outcome was no-reflow condition during primary PCI based on angiographic finding. The secondary clinical outcome was major adverse cardiovascular events (MACEs) comprising all-cause death, myocardial infarction, target vessel revascularization (TVR), and stent thrombosis.
RESULTS: Ten studies were finally included in this meta-analysis encompassing 3280 patients, which was predominantly male (76.6%). Postdilatation was performed in 40.7% cases. Postdilatation was associated with increased risk of no-reflow during primary PCI [Odd Ratio (OR) = 1.33, 95% Confidence Interval (CI): 1.12-1.58; P = .001)]. Conversely, postdilatation had a tendency to reduce MACE (OR = 0.70, 95% CI: 0.51-0.97; P = .03) specifically in terms of TVR (OR = 0.41, 95% CI: 0.22-0.74; P = .003). No significant differences between both groups in relation to mortality (OR = 0.58, 95% CI: 0.32-1.05; P = .07) and myocardial infarction (OR = 1.5, 95% CI: 0.78-2.89; P = .22).
CONCLUSIONS: Postdilatation after stent deployment during primary PCI appears to be associated with an increased risk of no-reflow phenomenon after the procedure. Nevertheless, postdilatation strategy has demonstrated a significant reduction in MACE over the course of long-term follow-up. Specifically, postdilatation significantly decreased the occurrence of TVR. Key messages: What is already known on this topic?  Optimizing stent deployment by performing postdilatation during percutaneous coronary intervention (PCI) is essential for long-term clinical outcomes. However, its application during primary PCI is controversial due to the fact that it may provoke distal embolization and worsen coronary blood flow. What this study adds?  In this systematic review and meta-analysis of 10 studies, we confirm that postdilatation during primary PCI is associated with worse coronary blood flow immediately following the procedure. On the contrary, this intervention proves advantageous in improving long-term clinical outcomes, particularly in reducing target vessel revascularization. How this study might affect research, practice, or policy?  Given the mixed impact of postdilatation during primary PCI, this strategy should only be applied selectively. Future research should focus on identifying patients who may benefit from such strategy.
The invention discloses a traditional Chinese medicine composition for treating chronic appendicitis. The traditional Chinese medicine composition consists of the following traditional Chinese medicines: 8-12g of rheum officinale, 8-12g of mirabilite, 10-15g of fructus forsythiae, 10-15g of honeysuckle, 10-20g of sargent gloryvine, 8-12g of rhizoma corydalis, 8-12g of elecampane, 8-12g of peach kernel and 10-15g of the root bark of the peony tree. The traditional Chinese medicine composition disclosed by the invention is decocted with water, and one dosage of the medicine is taken per day. The traditional Chinese medicine composition has the effects of clearing heat, relaxing the bowel and promoting qi to activate blood and is suitable for chronic appendicitis, unpalpable dull pain of the right lower abdomen, continuity or paroxysm, abdominal wall skin contracture, abdominal swelling anorexia, nausea, eructation, eupyrexia, irregular bowel movement or constipation. The symptoms refer to thin white or yellow and white coated tongue, wiry and rolling pulse, rapid pulse or fine and astringent pulse. Each traditional Chinese medicine in the traditional Chinese medicine composition disclosed by the invention has the own drug effect, and each function of the body is balanced and conditioned by using the traditional Chinese medicine composition, so that the aim of treating the chronic appendicitis is achieved.